In this article, we will discuss Rasburicase (Dosage Overview). So, let’s get started.
Rasburicase is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.
Limitation of use: Rasburicase is indicated only for a single course of treatment.
The recommended dose of Rasburicase is 0.2 mg/kg as a 30 minute intravenous infusion daily for up to 5 days. Dosing beyond 5 days or administration of more than one course is not recommended.